The rapid urease test (RUT) performed on gastric biopsy specimens provides the greatest diagnostic value when the result is interpreted in the context of specimen quality, patient exposure to medications (particularly proton pump inhibitors, antibiotics, and bismuth compounds), and adherence to the recommended reading window. In endoscopic practice, these elements — rather than the declared reaction time alone — significantly influence the risk of false-negative or clinically misleading results.

The rapid urease test (RUT) is one of the most commonly used methods during gastroscopy for the diagnosis of Helicobacter pylori infection. Its practical value derives from ease of use, relatively low cost, and short time to result. The test is based on the detection of bacterial urease activity in biopsy material obtained from the gastric mucosa [2].

However, RUT should not be evaluated solely on the basis of “speed.” The reliability of the result depends on procedural and interpretative conditions. Final diagnostic performance is influenced by the biopsy site and technique, specimen size, reaction conditions, and the timing of result interpretation. Therefore, in endoscopic practice, the overall quality of the pre-analytical and analytical process is as important as the test itself [2].

Scientific literature identifies several factors associated with an increased risk of false-negative RUT results, particularly prior exposure to proton pump inhibitors (PPIs), antibiotics, and bismuth preparations, as well as the presence of intestinal metaplasia. Consequently, RUT interpretation must take into account the broader clinical context rather than relying solely on color change or binary readout [2].

Contemporary H. pylori diagnostics include both endoscopic methods (e.g., histology, RUT) and non-endoscopic approaches (e.g., ¹³C-urea breath test, stool antigen test, serology). In a comparative study evaluating four diagnostic methods in patients referred for gastroscopy, a high concordance between RUT and histology was demonstrated within the analyzed population. The authors emphasized that test selection and interpretation should always be contextualized within real clinical and organizational settings [1].

When comparing rapid urease tests in endoscopic practice, declared “speed” should not be the primary selection criterion. The key consideration is the sensitivity of the result to pre-analytical variables and how these variables are controlled in routine clinical workflow. Factors significantly affecting RUT performance include biopsy location, specimen size, reaction temperature, and reading time. In practice, this means that two tests with similar declared parameters may differ substantially in clinical utility if they vary in tolerance to real-world operating conditions [2].

Biopsy topography is one of the most important comparative parameters. Sampling from both the antrum and corpus increases detection rates compared with strategies based on a single location, particularly in cases of uneven H. pylori colonization. Therefore, test evaluation should address not only whether the test “works,” but also under which biopsy protocol it was validated and whether the manufacturer clearly specifies recommendations regarding biopsy site selection [2].

A second critical parameter includes pharmacological and mucosal factors that reduce sensitivity: proton pump inhibitors, antibiotics, bismuth compounds, and intestinal metaplasia. These conditions are associated with an increased frequency of false-negative results. From the perspective of the endoscopy team, a product with clearly defined limitations and well-described interpretative recommendations for at-risk populations provides greater operational safety than one lacking explicit methodological guidance [2].

The third comparative parameter is the defined reading window and criteria for interpreting a negative result. Prolonged incubation increases the likelihood of late, non-specific reactions (including activity from other urease-producing microorganisms), reducing diagnostic specificity. A positive result obtained outside the recommended reading window carries lower diagnostic value than one interpreted within the validated timeframe. For endoscopy units, this necessitates careful comparison of tests with respect to clearly defined “decision windows” [2].

In practical comparisons prior to RUT implementation, tests should be evaluated based on four essential questions:

Only such structured analysis provides clinically meaningful comparison for gastroenterologists and endoscopy personnel.

In clinical settings, meaningful differentiation between rapid urease tests does not arise from marketing claims, but from four core elements: the required biopsy protocol (antrum/corpus), sensitivity to factors reducing diagnostic performance (PPIs, antibiotics, bismuth, metaplasia), clearly defined reading windows, and interpretative consistency within the local diagnostic framework. A test supported by precise sampling and reading guidelines and transparent documentation of limitations offers greater decision-making safety for endoscopic teams than a test promoted primarily on speed without robust methodological documentation. Therefore, RUT selection should be based on the quality of manufacturer data and predictable performance under routine clinical conditions, rather than solely on the declared time to result [1][2].